Meddenovo Drug Design announced that it has closed a pre-seed investment round of €1 million. This investment round was led by ACT Venture Partners. Meddenovo Drug Design was founded by Dr. İlke Uğur Marion and Dr. Antoine Marion. The company conducts pharmaceutical research by leveraging artificial intelligence, molecular modeling and the unique properties of peptides to create innovative therapeutic solutions.

Meddenovo Drug Design

Dr. İlke Uğur Marion: has a strong background in drug development, scientific research and project management. As CEO of the company, Dr. Ugur Marion emphasizes that their platform, specifically designed to harness the potential of peptides, has untapped potential in pharmaceutical research.
Dr. Antoine Marion: Expert in computational chemistry code development and design methods. He contributes significantly to the development of the company's platforms.

The investment from ACT Venture Partners will support Meddenovo's growth in several areas:

• Research and Development: Accelerating drug development and developing AI-driven platforms.
• Customer Base and Partnerships: Expand the company's customer base and establish new partnerships.
• Transition from Service to SaaS Model: Promote the transition from a service-based model to a Software as a Service (SaaS) model and increase co-development opportunities.

To further its mission, Meddenovo will continue its work in the following areas:

• Artificial Intelligence Platform Development: Advancing drug design by pushing the boundaries of therapeutic development.
• Expansion of the Team: Expanding the team to support the company's growth and engage in a wider range of projects.
• Establishing New Partnerships: Collaborate to create a broader impact and increase innovation capacity.

With this investment, Meddenovo aims to continue providing innovative solutions in drug design and shape the future of pharmaceutical research.